Skymab presented new preclinical data demonstrating the efficacy and safety profile of SKM104, its first-in-class anti-GPCR ADC, in pancreatic ductal adenocarcinoma.
These findings further support the broad therapeutic potential of the SKM104 program across difficult-to-treat cancers.